IBRX

ImmunityBio, Inc.

NantKwest Inc is a biotechnology firm operating mainly in the United States. It undertakes research and discovery of drugs to cure virally-induced cancers, bacterial and fungal diseases. Its pipeline product includes taNK, haNK, and aNK.

ImmunityBio, Inc. (IBRX) is scored daily on Deltasharpe Prism against Healthcare sector peers across five pillars: Value, Growth, Profitability, Momentum and Revisions.

Quantitative Factor Evaluation • Updated

Prism grades are automated quantitative screens, not buy, sell or hold recommendations, and not investment advice. Data may be delayed or contain errors. Terms

Ratings of B- and above are for members.

Register free to see every rating — your first 2 weeks of Premium are on us.

Register — 2 weeks free

Historical Factor Score Progression

Date Value Growth Profitability Momentum Revisions Overall
2026-11-12 C+ (2.8) A (4.3) A- (4.0) B- (2.9) C+ (2.6) B (3.3)
2026-11-05 C+ (2.7) A+ (4.6) A- (4.0) B- (3.0) C+ (2.7) B (3.4)
2026-10-29 C+ (2.7) A+ (4.6) A- (4.1) B (3.2) C+ (2.7) B (3.4)
2026-10-22 C+ (2.7) A+ (4.6) A- (4.1) B- (2.9) C+ (2.6) B (3.4)

Showing the last month only. Subscribe for the full factor score history.

For more — Subscribe